Zydus Wins Delhi HC Nod for Cheaper Cancer Drug Nivolumab

Introduction

In a significant judgment with wide-ranging implications for healthcare access in India, the Delhi High Court has allowed Zydus Lifesciences to manufacture and market a biosimilar version of the cancer immunotherapy drug, Nivolumab. The ruling, delivered on January 12, 2026, sets aside a previous injunction and prioritizes public interest, potentially making the life-saving treatment more affordable for thousands of patients. The decision came in a patent dispute with Bristol-Myers Squibb (BMS), the innovator company that markets the drug globally as Opdivo.

The Court's Landmark Decision

A division bench comprising Justices C. Hari Shankar and Om Prakash Shukla overturned a July 2025 order from a single-judge bench that had restrained Zydus from launching its product. The court reasoned that with the patent for Nivolumab set to expire on May 2, 2026, a complete injunction was not justified, especially given the drug's critical, life-saving nature. The bench observed that the "balance of convenience" lay in permitting the biosimilar's sale while safeguarding the patentee's interests. The court stated, "where the product in question is a life-saving drug, the Court has to err in favour of public interest… Withholding such therapy from the public can cause untold and irreparable prejudice to lakhs of lives."

Background of the Legal Dispute

The legal battle began in 2024 when E.R. Squibb & Sons LLC, a BMS group entity, filed a patent infringement suit against Zydus Lifesciences. BMS alleged that Zydus was preparing to commercially launch its biosimilar, ZRC-3276, before the patent's expiry. They argued that Zydus had already conducted clinical trials and sought regulatory approvals, indicating an imminent infringement. Zydus countered that its activities were protected under the 'Bolar exemption' in India's Patents Act, which permits research and development for submitting regulatory information before a patent expires. Zydus also challenged the validity of the original patent.

Safeguards for the Patent Holder

While ruling in favor of Zydus, the court implemented measures to protect Bristol-Myers Squibb's commercial interests pending the final outcome of the infringement suit. The bench directed Zydus to maintain meticulous and independently audited accounts of all revenue generated from the sale of its Nivolumab biosimilar.

This arrangement ensures that while public access to the drug is not delayed, the innovator company has a clear path to financial recourse if its patent is found to have been infringed.

The Drug at the Center: Nivolumab

Nivolumab is a breakthrough monoclonal antibody used in immunotherapy. It treats several types of cancer, including lung cancer, melanoma, and kidney cancer, by helping the body's own immune system identify and attack tumor cells. Marketed as Opdivo by BMS, the treatment has transformed patient outcomes. However, its high cost, often running into several lakh rupees per month, places it beyond the reach of most Indian patients. This high price point was a central element in the court's public interest considerations.

Market Impact and Patient Access

The entry of a Zydus biosimilar is expected to significantly disrupt the market and lower treatment costs. Industry analysts predict a potential price reduction of 30% to 40%, which could save patients lakhs of rupees over their course of treatment. This could fundamentally alter cancer care in India. Public hospitals, which currently ration the use of expensive immunotherapies, may be able to offer it to more patients. Furthermore, lower prices could encourage insurance companies to expand coverage for such advanced treatments, benefiting middle-class families.

Broader Implications for the Pharma Industry

The ruling has reignited the long-standing debate between pharmaceutical innovation and public health. Multinational pharmaceutical companies argue that strong patent protection is essential to justify the massive investments required for research and development. They express concern that rulings like this could weaken the patent regime and discourage future innovation. However, this decision aligns with a consistent trend in Indian jurisprudence, most famously established in the Supreme Court's 2013 Novartis v. Union of India case, which upheld strict standards for patentability to promote access to affordable medicines. The Delhi High Court's ruling is not a blanket rejection of patent rights but a selective intervention based on the specific context of a life-saving drug with a short remaining patent term.

Conclusion

The Delhi High Court's decision in the Zydus-BMS case is a crucial development in India's access-to-medicines landscape. By carefully balancing the rights of the patent holder with the urgent needs of cancer patients, the court has sent a clear signal that public health considerations can outweigh commercial interests, particularly for essential treatments. As Zydus prepares to launch its more affordable Nivolumab biosimilar, the focus will shift to how this increased access translates into tangible benefits for patients and the broader healthcare system. The real verdict will be measured in the lives that can be extended and the families relieved of crippling financial burdens.